Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shandong Weigao Group Medical Polymer Co EV-to-EBIT?
Shandong Weigao Group Medical Polymer CoSHWGF 57 EV-to-EBIT is 4.68 as of Jul. 30, 2026, which is 65% below its 10-year median of 13.29. GuruFocus rates SHWGF with a GF Scoreâ„¢ of 57/100 and a GF Valueâ„¢ of $0.86 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 91.88% on this metric.
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shandong Weigao Group Medical Polymer Co's Enterprise Value for the quarter that ended in Dec. 2025 was $2,714 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Weigao Group Medical Polymer Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $321 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co EV-to-EBIT Related Terms
Shandong Weigao Group Medical Polymer Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co EV-to-EBIT Chart
Shandong Weigao Group Medical Polymer Co Annual Data
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's EV-to-EBIT falls into.
Shandong Weigao Group Medical Polymer Co's current Enterprise Value is $1,503 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shandong Weigao Group Medical Polymer Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $321 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co (SHWGF) has a EV-to-EBIT of 4.68 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is 65% below median its historical median of 13.29. Over the past decade, Shandong Weigao Group Medical Polymer Co's EV-to-EBIT has ranged from 4.41 to 32.62. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #38 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 8.1%.
Is Shandong Weigao Group Medical Polymer Co's EV-to-EBIT too high?
Shandong Weigao Group Medical Polymer Co's current EV-to-EBIT of 4.68 is 65% below median its 10-year median of 13.29. Over the past 10 years, this metric has ranged from a low of 4.41 to a high of 32.62. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Shandong Weigao Group Medical Polymer Co's value of 4.68 is 75% below this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #38 out of 468 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #38 out of 468 companies for EV-to-EBIT. This places Shandong Weigao Group Medical Polymer Co in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.70. Shandong Weigao Group Medical Polymer Co's value of 4.68 is 75% below this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own EV-to-EBIT has ranged from 4.41 to 32.62 over the past decade. While the company's 10-year median is 13.29 vs. the industry median of 18.70, Shandong Weigao Group Medical Polymer Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current EV-to-EBIT of 4.68 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current EV-to-EBIT is 4.68, which is 65% below median its own 10-year median of 13.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.86, compared to a current price of $0.43 — trading 49.5% below its estimated fair value. The current EV-to-EBIT is 4.68, which is 65% below median its 10-year median of 13.29 and 75% below the Medical Devices & Instruments industry median of 18.70. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGF), the current EV-to-EBIT is 4.68 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGF) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $0.43 is trading 49.5% below its estimated GF Value™ of $0.86.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGF:
EV-to-EBIT: 4.68 (65% below median its 10-year median of 13.29)
GF Value™: $0.86 vs. price of $0.43 (49.5% below fair value)
Industry Position: 75% below the Medical Devices & Instruments median (#38 of 468)
No single metric tells the full story. See the SHWGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
57GF Score
Get the complete analysis for SHWGF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGF has been successfully added to your 
